Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss drugs towards the end of the year. Novo saw But Novo said Wednesday it expects slower growth in 2025 compared to the prior year.
Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...
Novo Nordisk, maker of the weight-loss drug Wegovy, faces potential challenges as U.S. President Trump threatens tariffs on ...
News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...
Wegovy sales increased by more than 100% over 2024. But that wasn’t enough to satiate analysts who want to know why Novo Nordisk can’t access more patients, particularly in the U.S.
Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...
Demand for weight loss jabs continues to surge, particularly as the NHS began offering Wegovy in late 2023 and will start offering Mounjaro to patients in March 2025. They have also become ...
1don MSN
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback